Skip to main content
Premium Trial:

Request an Annual Quote

Brooks Automation to Acquire GeneWiz

NEW YORK (GenomeWeb) — Genomics services provider GeneWiz said today that it has agreed to be acquired by Brooks Automation.

Terms of the transaction, which is expected to close by the end of the year, were not disclosed.

GeneWiz —which is headquartered in South Plainfield, New Jersey, and has locations throughout the US, Europe, and Asia — offers a variety of genomic services, including Sanger sequencing, gene synthesis, cloning and mutagenesis, oligo synthesis, and next-generation sequencing. Chelmsford, Massachusetts-based Brooks Automation provides automation and cryogenic products and services for a range of industries, and offers biological sample management solutions through its life sciences division.

"This is another milestone of Brooks' growth strategy in life sciences," Brooks Automation President and CEO Steve Schwartz said in a statement. "Having GeneWiz on board is consistent with our commitment to investing in the development and growth of the Brooks life sciences business."

About a year ago, Brooks Automation acquired UK-based scientific tools and consumables maker 4titude for $65 million in cash. In 2011, it bought automated compound and sample management solution company Nexus Biosystems for $79 million.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.